Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Interleukin-12 gene therapy vaccines: Directing the immune system against minimal residual leukemia
Autore:
Dunussi-Joannopoulos, K; Leonard, JP;
Indirizzi:
Inst Genet, Andover, MA 01810 USA Inst Genet Andover MA USA 01810Inst Genet, Andover, MA 01810 USA
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 5-6, volume: 41, anno: 2001,
pagine: 483 -
SICI:
1042-8194(200105)41:5-6<483:IGTVDT>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; TUMOR REJECTION ANTIGENS; CYTOLYTIC T-LYMPHOCYTES; ANTITUMOR IMMUNITY; INTERFERON-GAMMA; RECOMBINANT INTERLEUKIN-12; CANCER VACCINES; MURINE AML; CELLS;
Keywords:
interleukin-12; gene therapy; vaccines; immune system; minimal residual leukemia;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
61
Recensione:
Indirizzi per estratti:
Indirizzo: Dunussi-Joannopoulos, K Inst Genet, 1 Burtt Rd, Andover, MA 01810 USA InstGenet 1 Burtt Rd Andover MA USA 01810 810 USA
Citazione:
K. Dunussi-Joannopoulos e J.P. Leonard, "Interleukin-12 gene therapy vaccines: Directing the immune system against minimal residual leukemia", LEUK LYMPH, 41(5-6), 2001, pp. 483

Abstract

Current overall survival rates for patients with AML remain poor and thereis need for novel therapeutic approaches. One such approach is to use the patient's own immune system to eliminate minimal residual disease. Recent advances in genetic manipulation of tumor cells, together with a better understanding of the immune mechanisms controlling the host-tumor relationship have led to a flurry of preclinical and clinical studies on tumor cell vaccines. Here we present a brief overview of genetic manipulation of tumor cells, and highlight important principles of cancer immunity and cancer vaccines. Special emphasis is given on recent work on the role of interleukin 12 (IL-12) based vaccines in murine AML. These studies have shown that vaccines with AML cells, genetically modified to secrete IL-12, are potent stimulators of the immune system and lead to the development of both prophylactic and therapeutic anti-leukemia immunity.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/04/20 alle ore 13:23:18